Alto Neuroscience (NYSE:ANRO) Shares Down 5.5% – What’s Next?

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) traded down 5.5% on Monday . The stock traded as low as $26.37 and last traded at $26.0350. Approximately 270,408 shares changed hands during mid-day trading, a decline of 26% from the average session volume of 363,358 shares. The stock had previously closed at $27.54.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wall Street Zen raised Alto Neuroscience from a “strong sell” rating to a “sell” rating in a report on Saturday. Wedbush raised their price objective on Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Chardan Capital reiterated a “buy” rating and set a $30.00 target price on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Bank of America began coverage on Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Wolfe Research started coverage on Alto Neuroscience in a research report on Friday, May 22nd. They set an “outperform” rating on the stock. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Stock Down 4.4%

The firm has a market capitalization of $923.60 million, a price-to-earnings ratio of -10.99 and a beta of 1.04. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The firm has a 50 day moving average of $23.17 and a two-hundred day moving average of $21.20.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, sell-side analysts anticipate that Alto Neuroscience, Inc. will post -3.01 EPS for the current fiscal year.

Institutional Trading of Alto Neuroscience

Several institutional investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Alto Neuroscience by 14,567.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock worth $3,786,000 after acquiring an additional 211,222 shares during the period. Artia Global Partners LP bought a new position in Alto Neuroscience during the 4th quarter worth approximately $520,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Alto Neuroscience during the first quarter worth $538,000. Perceptive Advisors LLC lifted its stake in shares of Alto Neuroscience by 1,048.5% in the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after purchasing an additional 1,629,027 shares during the period. Finally, Spruce Street Capital LP bought a new stake in shares of Alto Neuroscience during the 4th quarter valued at about $3,967,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.